ZA200100092B - Chemotaxis-inhibiting protein of staphylococcus (chips) and its use. - Google Patents

Chemotaxis-inhibiting protein of staphylococcus (chips) and its use. Download PDF

Info

Publication number: ZA200100092B
Authority: ZA; South Africa
Prior art keywords: column; protein; chips; biologically active; chromatography column
Prior art date: 1998-07-10

Application number

ZA200100092A

Other languages

English (en)

Inventor

Johannes Van Strijp

Gerardus Antonius

Cornelis Van Kessel

Maria Petrus

Original Assignee

Jari Pharmaceuticals B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

2001-01-04

Publication date

2001-07-23

2001-01-04 Application filed by Jari Pharmaceuticals B V filed Critical Jari Pharmaceuticals B V

2001-07-23 Publication of ZA200100092B publication Critical patent/ZA200100092B/en

Links

102000004169 proteins and genes Human genes 0.000 title claims description 33
108090000623 proteins and genes Proteins 0.000 title claims description 33
230000035605 chemotaxis Effects 0.000 title claims description 12
241000191940 Staphylococcus Species 0.000 title claims description 6
230000002401 inhibitory effect Effects 0.000 title claims description 5
101710191541 Chemotaxis inhibitory protein Proteins 0.000 claims description 48
210000004027 cell Anatomy 0.000 claims description 24
210000003714 granulocyte Anatomy 0.000 claims description 21
238000000034 method Methods 0.000 claims description 19
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 16
238000010521 absorption reaction Methods 0.000 claims description 14
239000012634 fragment Substances 0.000 claims description 14
238000004587 chromatography analysis Methods 0.000 claims description 12
238000012360 testing method Methods 0.000 claims description 12
239000003446 ligand Substances 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 9
241000191967 Staphylococcus aureus Species 0.000 claims description 8
208000038016 acute inflammation Diseases 0.000 claims description 8
230000006022 acute inflammation Effects 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
208000031886 HIV Infections Diseases 0.000 claims description 7
208000037357 HIV infectious disease Diseases 0.000 claims description 7
239000002975 chemoattractant Substances 0.000 claims description 7
208000037976 chronic inflammation Diseases 0.000 claims description 7
230000006020 chronic inflammation Effects 0.000 claims description 7
238000002523 gelfiltration Methods 0.000 claims description 7
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 7
238000000746 purification Methods 0.000 claims description 7
238000001042 affinity chromatography Methods 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
239000012228 culture supernatant Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
230000004071 biological effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
229940088623 biologically active substance Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 28
102000005962 receptors Human genes 0.000 description 22
108020003175 receptors Proteins 0.000 description 22
102000019034 Chemokines Human genes 0.000 description 11
108010012236 Chemokines Proteins 0.000 description 11
238000011534 incubation Methods 0.000 description 9
239000000975 dye Substances 0.000 description 8
102000009410 Chemokine receptor Human genes 0.000 description 7
108050000299 Chemokine receptor Proteins 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 6
108010076288 Formyl peptide receptors Proteins 0.000 description 6
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 6
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000003399 chemotactic effect Effects 0.000 description 6
102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000000463 material Substances 0.000 description 5
239000000523 sample Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920000936 Agarose Polymers 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000000470 constituent Substances 0.000 description 4
230000007646 directional migration Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
102000001902 CC Chemokines Human genes 0.000 description 3
108010040471 CC Chemokines Proteins 0.000 description 3
108050006947 CXC Chemokine Proteins 0.000 description 3
102000019388 CXC chemokine Human genes 0.000 description 3
102000004890 Interleukin-8 Human genes 0.000 description 3
108090001007 Interleukin-8 Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
238000010828 elution Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000009087 cell motility Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
229940096397 interleukin-8 Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
102000004274 CCR5 Receptors Human genes 0.000 description 1
108010017088 CCR5 Receptors Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000001327 Chemokine CCL5 Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
108050002052 Chemotaxis inhibitory proteins Proteins 0.000 description 1
101710139422 Eotaxin Proteins 0.000 description 1
102100023688 Eotaxin Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
-1 N-formyl-Methionyl- Chemical group 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
239000005667 attractant Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000031902 chemoattractant activity Effects 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000010432 diamond Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
102000010681 interleukin-8 receptors Human genes 0.000 description 1
108010038415 interleukin-8 receptors Proteins 0.000 description 1
KFKWRHQBZQICHA-UHFFFAOYSA-N leucyl-phenylalanine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-UHFFFAOYSA-N 0.000 description 1
108010044056 leucyl-phenylalanine Proteins 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000030505 negative regulation of chemotaxis Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200100092A 1998-07-10 2001-01-04 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use. ZA200100092B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NL1009614		1998-07-10

Publications (1)

Publication Number	Publication Date
ZA200100092B true ZA200100092B (en)	2001-07-23

Family

ID=19767471

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200100092A ZA200100092B (en)	1998-07-10	2001-01-04	Chemotaxis-inhibiting protein of staphylococcus (chips) and its use.

Country Status (22)

Country	Link
US (2)	US20050143307A1 (fr)
EP (1)	EP1095059B1 (fr)
JP (1)	JP2002520336A (fr)
KR (1)	KR20010053290A (fr)
CN (1)	CN1309662A (fr)
AT (1)	ATE328898T1 (fr)
AU (1)	AU4935999A (fr)
BG (1)	BG105120A (fr)
BR (1)	BR9911944A (fr)
CA (1)	CA2333898A1 (fr)
CY (1)	CY1105343T1 (fr)
DE (1)	DE69931784T2 (fr)
DK (1)	DK1095059T3 (fr)
ES (1)	ES2270609T3 (fr)
HU (1)	HUP0102975A2 (fr)
IL (1)	IL140768A0 (fr)
NO (1)	NO20010140L (fr)
NZ (1)	NZ509051A (fr)
PL (1)	PL345452A1 (fr)
PT (1)	PT1095059E (fr)
WO (1)	WO2000002913A1 (fr)
ZA (1)	ZA200100092B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1309662A (zh) *	1998-07-10	2001-08-22	亚利制药有限公司	葡萄球菌属的趋化性抑制蛋白(chips)及其应用
EP1118663A1 (fr) *	2000-01-07	2001-07-25	Universiteit Utrecht	Acides nucléiques codant des protéines inhibitrices de la chimiotaxie
US20020086292A1 (en)	2000-12-22	2002-07-04	Shigeaki Harayama	Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2003006048A1 (fr) *	2001-07-11	2003-01-23	Jari Pharmaceuticals B.V.	Combinaison de composes a base de chips (proteine inhibant la chimiotaxie de staphylococcus aureus)
ES2360399T3 (es) *	2003-07-08	2011-06-03	Umc Utrecht Holding B.V.	Uso terapéutico de lpi, un inhibidor de la vía de las lectinas de origen estafilocócico, en enfermedades inflamatorias.
EP1586583A3 (fr) *	2004-04-16	2005-11-16	Alligator Bioscience AB (publ)	Composés qui bloquent le récepteur du complément C5a et leur utilisation en thérapie
US20090186111A1 (en)	2004-07-26	2009-07-23	Zeev Trainin	Novel Bacteria and Pharmaceutically Active Products Obtained Therefrom
GB2432366B (en) *	2005-11-19	2007-11-21	Alligator Bioscience Ab	A method for in vitro molecular evolution of protein function
GB0607798D0 (en) *	2006-04-20	2006-05-31	Alligator Bioscience Ab	Novel polypeptides and use thereof
GB0905790D0 (en)	2009-04-03	2009-05-20	Alligator Bioscience Ab	Novel polypeptides and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772584A (en) *	1986-05-23	1988-09-20	Cleary Paul P	Inhibitor of C5a-mediated chemotaxis
AU2509592A (en) *	1991-08-22	1993-03-16	Washington University	Polynucleotide probes for salmonella
US5514555A (en) *	1993-03-12	1996-05-07	Center For Blood Research, Inc.	Assays and therapeutic methods based on lymphocyte chemoattractants
US5514455A (en) *	1994-07-08	1996-05-07	Union Carbide Chemicals & Plastics Technology Corporation	Film extruded from an in situ blend of ethylene copolymers
US5817476A (en) *	1995-06-07	1998-10-06	Genetics Institute, Inc.	Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US7153655B2 (en) *	1998-06-16	2006-12-26	Alligator Bioscience Ab	Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
CN1309662A (zh) *	1998-07-10	2001-08-22	亚利制药有限公司	葡萄球菌属的趋化性抑制蛋白(chips)及其应用
JP3722194B2 (ja) *	1999-05-20	2005-11-30	セイコーエプソン株式会社	画像表示システム
EP1118663A1 (fr) *	2000-01-07	2001-07-25	Universiteit Utrecht	Acides nucléiques codant des protéines inhibitrices de la chimiotaxie
US6958213B2 (en) *	2000-12-12	2005-10-25	Alligator Bioscience Ab	Method for in vitro molecular evolution of protein function
US20020086292A1 (en) *	2000-12-22	2002-07-04	Shigeaki Harayama	Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
DK1504098T4 (da) *	2002-05-17	2011-05-23	Alligator Bioscience Ab	Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion

1999
- 1999-07-12 CN CN99808416A patent/CN1309662A/zh active Pending
- 1999-07-12 CA CA002333898A patent/CA2333898A1/fr not_active Abandoned
- 1999-07-12 AT AT99933284T patent/ATE328898T1/de not_active IP Right Cessation
- 1999-07-12 JP JP2000559142A patent/JP2002520336A/ja active Pending
- 1999-07-12 AU AU49359/99A patent/AU4935999A/en not_active Abandoned
- 1999-07-12 IL IL14076899A patent/IL140768A0/xx unknown
- 1999-07-12 DE DE69931784T patent/DE69931784T2/de not_active Expired - Lifetime
- 1999-07-12 HU HU0102975A patent/HUP0102975A2/hu unknown
- 1999-07-12 WO PCT/NL1999/000442 patent/WO2000002913A1/fr not_active Ceased
- 1999-07-12 EP EP99933284A patent/EP1095059B1/fr not_active Expired - Lifetime
- 1999-07-12 DK DK99933284T patent/DK1095059T3/da active
- 1999-07-12 KR KR1020007015012A patent/KR20010053290A/ko not_active Withdrawn
- 1999-07-12 NZ NZ509051A patent/NZ509051A/xx unknown
- 1999-07-12 PL PL99345452A patent/PL345452A1/xx unknown
- 1999-07-12 ES ES99933284T patent/ES2270609T3/es not_active Expired - Lifetime
- 1999-07-12 BR BR9911944-7A patent/BR9911944A/pt not_active IP Right Cessation
- 1999-07-12 PT PT99933284T patent/PT1095059E/pt unknown
2001
- 2001-01-04 ZA ZA200100092A patent/ZA200100092B/en unknown
- 2001-01-08 BG BG105120A patent/BG105120A/xx unknown
- 2001-01-09 NO NO20010140A patent/NO20010140L/no unknown
2005
- 2005-02-22 US US11/063,324 patent/US20050143307A1/en not_active Abandoned
2006
- 2006-09-06 CY CY20061101273T patent/CY1105343T1/el unknown
2007
- 2007-03-27 US US11/691,745 patent/US20080242605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1095059T3 (da)	2006-10-02
IL140768A0 (en)	2002-02-10
US20080242605A1 (en)	2008-10-02
EP1095059B1 (fr)	2006-06-07
ATE328898T1 (de)	2006-06-15
CN1309662A (zh)	2001-08-22
CY1105343T1 (el)	2010-03-03
BR9911944A (pt)	2001-09-25
AU4935999A (en)	2000-02-01
NZ509051A (en)	2003-01-31
WO2000002913A1 (fr)	2000-01-20
DE69931784D1 (de)	2006-07-20
DE69931784T2 (de)	2007-06-14
KR20010053290A (ko)	2001-06-25
BG105120A (en)	2001-11-30
JP2002520336A (ja)	2002-07-09
HUP0102975A2 (hu)	2001-11-28
US20050143307A1 (en)	2005-06-30
NO20010140D0 (no)	2001-01-09
PT1095059E (pt)	2006-10-31
NO20010140L (no)	2001-03-01
ES2270609T3 (es)	2007-04-01
EP1095059A1 (fr)	2001-05-02
PL345452A1 (en)	2001-12-17
WO2000002913B1 (fr)	2000-03-30
CA2333898A1 (fr)	2000-01-20

Publication	Publication Date	Title
US20080242605A1 (en)	2008-10-02	Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
EP0413908B1 (fr)	1996-09-25	Fragment extracellulaire soluble du recepteur IFN-bêta 2/IL-6 humain, sa préparation et composition pharmaceutique le contenant
Van Der Poll et al.	1994	Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
EP0412486B1 (fr)	1994-11-30	Anticorps contre la protéine de liaison I au facteur de nécrose tumorale (TNF) et leurs fragments F(ab)
Lanar et al.	1986	Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice
CA1337518C (fr)	1995-11-07	Anticorps monoclonaux diriges contre le tnf-, des hybridomes produisant ces anticorps et une methode de purification de la tnf-
DE69330087T2 (de)	2001-08-02	System zur lokalisierung und kommunikation mit mobilen fahrzeugen
Taverne et al.	1984	Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum
JPH0742317B2 (ja)	1995-05-10	インタ−フエロン蛋白とその製造法
JP2012501708A (ja)	2012-01-26	炎症性状態の治療
Yoshida et al.	1975	The production of anti-guinea pig lymphokine antibody
Griffiths-Johnson et al.	1997	[16] Animal models of asthma: Role of chemokines
Kambara et al.	1977	The chemical mediation of delayed hypersensitivity skin reactions. I. Purification of a macrophage-chemotactic factor from bovien gamma-globulin-induced skin reactions in guinea pigs
Vaickus et al.	1990	Interferon gamma augments Lym-1-dependent, granulocyte-mediated tumor cell lysis
EP1244790B1 (fr)	2010-12-01	Acides nucleiques codant pour des (poly)peptides ayant une activite de chips
Kuratsuji et al.	1976	Anti-lymphokine antibody: II. Specificity of biological activity
Shigeoka et al.	1988	Neutrophil mobilization induced by complement fragments during experimental group B streptococcal (GBS) infection
US5322838A (en)	1994-06-21	Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation
Ware et al.	1981	Mechanisms of lymphocyte-mediated cytotoxicity. II. biochemical and serologic identification of a precursor lymphotoxin form (pre-LT) produced by MLC-sensitized human T lymphocytes in vitro.
de Azavedo et al.	1988	Induction of tumour necrosis factor by staphylococcal toxic shock toxin 1
Rot	1996	In flammatory and physiological roles of chemokines
Goren et al.	1980	Normal immunosuppressive protein. Isolation of a glycoprotein active fraction
Potter et al.	1987	Separation and purification of lymphocyte chemotactic factor (LCF) and interleukin 2 produced by human peripheral blood mononuclear cells
Tanabe et al.	1995	Leukocyte-derived neutrophil chemotactic factor-2 produced by infiltrated leukocytes in allergic inflammation model in rats is macrophage inflammatory protein-2
Geczy	1980	Characterization of guinea pig mitogenic factors—II: A comparison of some biochemical parameters of mitogen-induced and antigen-induced factors